81 related articles for article (PubMed ID: 24566948)
1. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Gross ME; Pinski JK; Quinn DI
Clin Nucl Med; 2012 Jul; 37(7):637-43. PubMed ID: 22691503
[TBL] [Abstract][Full Text] [Related]
2. Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.
Gotto GT; Yu C; Bernstein M; Eastham JA; Kattan MW
Front Oncol; 2014; 4():296. PubMed ID: 25386410
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 IN metastatic hormone-sensitive high-grade prostate cancer: initial experience.
Osvaldo GF; Salvador MS; Zael SR; Nora SM
Am J Nucl Med Mol Imaging; 2017; 7(5):236-245. PubMed ID: 29181271
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process.
Demirkol MO; Acar Ö; Uçar B; Ramazanoğlu SR; Sağlıcan Y; Esen T
Prostate; 2015 May; 75(7):748-57. PubMed ID: 25598074
[TBL] [Abstract][Full Text] [Related]
6. Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases.
Chondrogiannis S; Marzola MC; Grassetto G; Rampin L; Massaro A; Colletti PM; Rubello D
Clin Nucl Med; 2015 Jun; 40(6):e308-12. PubMed ID: 25742236
[TBL] [Abstract][Full Text] [Related]
7. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
Ceci F; Herrmann K; Castellucci P; Graziani T; Bluemel C; Schiavina R; Vollmer C; Droll S; Brunocilla E; Mazzarotto R; Buck AK; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2222-31. PubMed ID: 25182750
[TBL] [Abstract][Full Text] [Related]
8. Choline-PET in prostate cancer management: the point of view of the radiation oncologist.
De Bari B; Alongi F; Lestrade L; Giammarile F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):234-47. PubMed ID: 24813466
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer.
Jadvar H; Colletti PM
PET Clin; 2022 Jul; 17(3):389-397. PubMed ID: 35662493
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis.
Kairemo K; Kappadath SC; Joensuu T; Macapinlac HA
Diagnostics (Basel); 2020 Dec; 11(1):. PubMed ID: 33374148
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Performance of [
Paymani Z; Rohringer T; Vali R; Loidl W; Alemohammad N; Geinitz H; Langsteger W; Beheshti M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708097
[TBL] [Abstract][Full Text] [Related]
12. The effect of androgen deprivation therapy on
Onal C; Guler OC; Torun N; Reyhan M; Yapar AF
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer imaging: when the game gets tough, the hard one gets done!
Evangelista L; Sepulcri M; Maruzzo M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2032-2034. PubMed ID: 30032321
[No Abstract] [Full Text] [Related]
14. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Cuccurullo V; Di Stasio GD; Mansi L
World J Nucl Med; 2018; 17(2):70-78. PubMed ID: 29719480
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
Gillebert Q; Huchet V; Rousseau C; Cochet A; Olivier P; Courbon F; Gontier E; Nataf V; Balogova S; Talbot JN;
PLoS One; 2018; 13(2):e0191487. PubMed ID: 29425221
[TBL] [Abstract][Full Text] [Related]
16. Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent.
Gauvin S; Cerantola Y; Haberer E; Pelsser V; Probst S; Bladou F; Anidjar M
Can Urol Assoc J; 2017; 11(1-2):47-52. PubMed ID: 28443145
[TBL] [Abstract][Full Text] [Related]
17. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.
Giovacchini G; Giovannini E; Leoncini R; Riondato M; Ciarmiello A
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1751-1776. PubMed ID: 28409220
[TBL] [Abstract][Full Text] [Related]
18. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
19. Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
Chondrogiannis S; Marzola MC; Ferretti A; Grassetto G; Maffione AM; Rampin L; Fanti S; Giammarile F; Rubello D
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1293-300. PubMed ID: 24566948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
